Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -33.34% is 53% above its 5-year average of -70.59%, near the high end of its 5-year range (-157.76%–-15.79%).
As of the fiscal period ended Tuesday, June 30, 2026. 40.78% above its 12-month average of -56.30%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): -10.70%.
RETURN ON ASSETS (ROA)
-33.34%
RETURN ON ASSETS (ROA) AVG TTM
-56.30%
RETURN ON ASSETS (ROA) AVG 3Y
-89.26%
RETURN ON ASSETS (ROA) AVG 5Y
-70.59%
RETURN ON ASSETS (ROA) AVG 10Y
-54.10%
RETURN ON ASSETS (ROA) AVG 15Y
-47.95%
RETURN ON ASSETS (ROA) AVG 20Y
-47.46%
CURRENT VS TTM AVG
+40.78%
CURRENT VS 3Y AVG
+62.65%
CURRENT VS 5Y AVG
+52.77%
CURRENT VS 10Y AVG
+38.38%
CURRENT VS 15Y AVG
+30.47%
CURRENT VS 20Y AVG
+29.75%
SECTOR MEDIAN · HEALTHCARE
-29.61%
median of 622 covered companies
CURRENT VS SECTOR MEDIAN
-12.58%
vs the sector median at left
iBio, Inc.
Market Cap
$68.49M
Return on Assets (ROA)
-33.34%
TTM Avg
-56.30%
3Y Avg
-89.26%
5Y Avg
-70.59%
Market Cap
$69.26M
Return on Assets (ROA)
-3.41%
TTM Avg
5.09%
3Y Avg
-8.30%
5Y Avg
-5.06%
Market Cap
$67.60M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$66.27M
Return on Assets (ROA)
-87.09%
TTM Avg
-130.17%
3Y Avg
-272.35%
5Y Avg
-217.34%
Market Cap
$70.95M
Return on Assets (ROA)
-99.89%
TTM Avg
-66.19%
3Y Avg
-52.51%
5Y Avg
-39.81%
Market Cap
$64.71M
Return on Assets (ROA)
-13.50%
TTM Avg
-6.86%
3Y Avg
-33.98%
5Y Avg
-45.40%
Market Cap
$64.94M
Return on Assets (ROA)
-162.91%
TTM Avg
-58.42%
3Y Avg
-64.67%
5Y Avg
-61.98%
Market Cap
$64.68M
Return on Assets (ROA)
-5.05%
TTM Avg
-7.03%
3Y Avg
-4.31%
5Y Avg
-4.67%
Market Cap
$72.94M
Return on Assets (ROA)
-130.37%
TTM Avg
-128.36%
3Y Avg
-112.34%
5Y Avg
-87.04%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iBio, Inc. (IBIO) | $68.49M | -33.34% | -56.30% | -89.26% | -70.59% |
| Champions Oncology, Inc. (CSBR)vs › | $69.26M | -3.41% | 5.09% | -8.30% | -5.06% |
| Fortress Biotech, Inc. (FBIO)vs › | $67.60M | 35.31% | -14.11% | -23.46% | -20.68% |
| Cingulate Inc. (CING)vs › | $66.27M | -87.09% | -130.17% | -272.35% | -217.34% |
| MindWalk Holdings Corp. (HYFT)vs › | $70.95M | -99.89% | -66.19% | -52.51% | -39.81% |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.71M | -13.50% | -6.86% | -33.98% | -45.40% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.94M | -162.91% | -58.42% | -64.67% | -61.98% |
| InterCure Ltd. (INCR)vs › | $64.68M | -5.05% | -7.03% | -4.31% | -4.67% |
| Gain Therapeutics, Inc. (GANX)vs › | $72.94M | -130.37% | -128.36% | -112.34% | -87.04% |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.30M | -44.47% | -42.63% | -230.85% | -167.04% |
ROA
-33.3%
ROE
-38.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | -33.34% |
| 2025-06-30 | -79.26% |
| 2024-06-30 | -86.68% |
| 2023-06-30 | -157.76% |
| 2022-06-30 | -50.69% |
| 2021-06-30 | -15.79% |
| 2020-06-30 | -17.45% |
| 2019-06-30 | -57.52% |
| 2018-06-30 | -37.38% |
| 2017-06-30 | -40.36% |
| 2016-06-30 | -18.92% |
| 2015-06-30 | -53.03% |
| 2014-06-30 | -56.45% |
| 2013-06-30 | -66.26% |
| 2012-06-30 | -58.13% |
| 2011-06-30 | -165.52% |
| 2010-06-30 | -123.28% |
| 2009-06-30 | -38.68% |
| 2008-06-30 | -52.66% |
| 2007-06-30 | -44.21% |
